+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antidepressants Drugs Market - Global Forecast 2026-2032- Product Image
Antidepressants Drugs Market - Global Forecast 2026-2032- Product Image
New

Antidepressants Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 198 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5715760
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antidepressant drugs market is in a period of transition as scientific progress, changing patient expectations, new regulatory demands, and shifting commercial models redefine the opportunities and risks faced by pharmaceutical and healthcare leaders. Stakeholders require robust insights to adapt strategies, maintain value, and drive sustainable patient outcomes.

Market Snapshot

The Antidepressants Drugs Market grew from USD 24.80 billion in 2025 to USD 26.93 billion in 2026. It is expected to continue growing at a CAGR of 10.36%, reaching USD 49.46 billion by 2032. This momentum is propelled by advances in neurobiological understanding, innovation in drug mechanisms and formulations, and increased focus on addressing unmet needs in depressive and anxiety disorders. Regulatory developments and evolving reimbursement systems also influence access and market dynamics, affecting decision-making across research, clinical, and commercial functions.

Scope & Segmentation

This report provides a detailed assessment of the antidepressant therapeutics landscape through robust market segmentation and regional analysis, enabling senior decision-makers to locate growth vectors and anticipate shifts in demand:

  • Drug Classes: Atypical antidepressants (bupropion, mirtazapine, trazodone), selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors.
  • Product Types: Branded and generic antidepressant products.
  • Administration Routes: Oral, parenteral (injection or infusion), and transdermal options that improve adherence and enable tailored delivery.
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy networks, each presenting distinct fulfillment and reimbursement dynamics.
  • Therapeutic Applications: Bipolar depression, generalized anxiety disorder (including panic, PTSD, social anxiety), major depressive disorder (with subgroups such as postpartum and treatment-resistant depression), obsessive-compulsive disorder, and seasonal affective disorder.
  • Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific, with attention to regulatory, payer, and access differences.
  • Technology Trends: Formulation science (extended-release, parenteral, transdermal), digital health tools, and decentralized evidence generation shaping the path from innovation to adoption.

Key Takeaways

  • Mechanistic advances are fostering differentiated product profiles, supporting a shift from legacy monoamine-centric molecules to therapies addressing neurotrophic and inflammatory pathways.
  • Formulation innovation—such as rapid-onset and adherence-optimized drug delivery—opens new market opportunities and influences prescriber and patient choice.
  • Digital platforms and decentralized clinical trials improve evidence quality and patient engagement, contributing to payer negotiations and accelerating market access.
  • Region-specific dynamics demand flexible commercialization and educational tactics, as infrastructure, cultural attitudes, and coverage models shape market entry and uptake.
  • Channel strategies must be adapted to address differing demands and touchpoints within hospital, retail, and online pharmacy environments for optimum market penetration.
  • Sustained success depends on integrated investment across clinical development, supply chain agility, and the expansion of patient-centric support programs.

Tariff Impact

Imminent 2025 tariff adjustments in the United States introduce new sourcing and procurement complexities for the pharmaceutical industry. Companies are adjusting supply chain configurations, increasing inventory, and qualifying alternative suppliers to offset potential cost increases and disruptions. These actions impact commercial launches, distribution planning, and pricing strategies. Navigating these changes requires ongoing vigilance to quality and regulatory compliance, while balancing cost management with secure supply and continuous patient access.

Methodology & Data Sources

Our analysis integrates peer-reviewed clinical literature, regulatory filings, product labeling, public company disclosures, and interviews with leading clinicians, payers, and supply experts. High-quality randomized trials, meta-analyses, and real-world studies underpin all efficacy and safety assessments. Qualitative and quantitative insights are triangulated with operational and policy reviews for comprehensive, actionable market intelligence.

Why This Report Matters

  • Enables executive teams to anticipate evolving scientific, clinical, and commercial trends supporting agile strategy development.
  • Guides resource allocation by identifying high-potential segments, geographies, and technologies for investment.
  • Supports risk management through analysis of regulatory, supply chain, and competitive challenges likely to shape outcomes.

Conclusion

As innovation and policy drivers reshape the antidepressant drugs market, organizations must align scientific, operational, and commercial priorities to realize sustained value. This report provides leaders with the essential insights to inform strategy, support growth, and strengthen market positioning.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Antidepressants Drugs Market, by Drug Class
8.1. Atypical Antidepressant
8.1.1. Bupropion
8.1.2. Mirtazapine
8.1.3. Trazodone
8.2. Monoamine Oxidase Inhibitor
8.3. Selective Serotonin Reuptake Inhibitor
8.4. Serotonin Noradrenaline Reuptake Inhibitor
8.5. Tricyclic Antidepressant
9. Antidepressants Drugs Market, by Product Type
9.1. Branded
9.2. Generic
10. Antidepressants Drugs Market, by Administration Route
10.1. Oral
10.2. Parenteral
10.3. Transdermal
11. Antidepressants Drugs Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Antidepressants Drugs Market, by Therapeutic Application
12.1. Bipolar Depression
12.2. Generalized Anxiety Disorder
12.2.1. Panic Disorder
12.2.2. Post Traumatic Stress Disorder
12.2.3. Social Anxiety Disorder
12.3. Major Depressive Disorder
12.3.1. Postpartum Depression
12.3.2. Treatment Resistant Depression
12.4. Obsessive Compulsive Disorder
12.5. Seasonal Affective Disorder
13. Antidepressants Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Antidepressants Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Antidepressants Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Antidepressants Drugs Market
17. China Antidepressants Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Alkermes plc
18.7. Allergan plc
18.8. Apotex Inc.
18.9. AstraZeneca PLC
18.10. Aurobindo Pharma Limited
18.11. Bristol-Myers Squibb Company
18.12. Eli Lilly and Company
18.13. GlaxoSmithKline plc
18.14. Hikma Pharmaceuticals PLC
18.15. Johnson & Johnson
18.16. Lundbeck A/S
18.17. Lupin Limited
18.18. Merck & Co., Inc.
18.19. Mylan N.V.
18.20. Novartis AG
18.21. Otsuka Holdings Co., Ltd.
18.22. Pfizer Inc.
18.23. Sanofi S.A.
18.24. Sun Pharmaceutical Industries Ltd.
18.25. Takeda Pharmaceutical Company Limited
18.26. Teva Pharmaceutical Industries Ltd.
18.27. Torrent Pharmaceuticals Ltd.
18.28. Viatris Inc.
18.29. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTIDEPRESSANTS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY BUPROPION, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY BUPROPION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY BUPROPION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MIRTAZAPINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MIRTAZAPINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MIRTAZAPINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRAZODONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRAZODONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRAZODONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MONOAMINE OXIDASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MONOAMINE OXIDASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MONOAMINE OXIDASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEROTONIN NORADRENALINE REUPTAKE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEROTONIN NORADRENALINE REUPTAKE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEROTONIN NORADRENALINE REUPTAKE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY BIPOLAR DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY BIPOLAR DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY BIPOLAR DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PANIC DISORDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PANIC DISORDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PANIC DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY POST TRAUMATIC STRESS DISORDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY POST TRAUMATIC STRESS DISORDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY POST TRAUMATIC STRESS DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SOCIAL ANXIETY DISORDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SOCIAL ANXIETY DISORDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SOCIAL ANXIETY DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY POSTPARTUM DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY POSTPARTUM DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY POSTPARTUM DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEASONAL AFFECTIVE DISORDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEASONAL AFFECTIVE DISORDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEASONAL AFFECTIVE DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 125. EUROPE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. EUROPE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 127. EUROPE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 128. EUROPE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 129. EUROPE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 130. EUROPE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. EUROPE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 132. EUROPE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 133. EUROPE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 143. AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 145. AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 146. AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 147. AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 148. AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 150. AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 151. AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 162. ASEAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. ASEAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 164. ASEAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 165. ASEAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 166. ASEAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 167. ASEAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. ASEAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 169. ASEAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 170. ASEAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 171. GCC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. GCC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 173. GCC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 174. GCC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 175. GCC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 176. GCC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. GCC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 178. GCC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 179. GCC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 189. BRICS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. BRICS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 191. BRICS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 192. BRICS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 193. BRICS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 194. BRICS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. BRICS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 196. BRICS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 197. BRICS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 198. G7 ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. G7 ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 200. G7 ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 201. G7 ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 202. G7 ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 203. G7 ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. G7 ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 205. G7 ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 206. G7 ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 207. NATO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. NATO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 209. NATO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 210. NATO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 211. NATO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 212. NATO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 213. NATO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 214. NATO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 215. NATO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 216. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)
TABLE 226. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 227. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 228. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATYPICAL ANTIDEPRESSANT, 2018-2032 (USD MILLION)
TABLE 229. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 230. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 231. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 232. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 233. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY GENERALIZED ANXIETY DISORDER, 2018-2032 (USD MILLION)
TABLE 234. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Antidepressants Drugs market report include:
  • AbbVie Inc.
  • Alkermes plc
  • Allergan plc
  • Apotex Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Lundbeck A/S
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages198
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 26.93 Billion
Forecasted Market Value ( USD ) by 2032 $ 49.46 Billion
Compound Annual Growth Rate10.3%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Antidepressant Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Antidepressant Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 140 Pages
  • Global
From
Noradrenergic & Specific Serotonergic Antidepressants Market - Global Forecast 2025-2030 - Product Image

Noradrenergic & Specific Serotonergic Antidepressants Market - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Antidepressants Market Report 2025 - Product Image

Antidepressants Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Antidepressants Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Antidepressants Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Antidepressants - Global Strategic Business Report - Product Image

Antidepressants - Global Strategic Business Report

  • Report
  • 174 Pages
  • Global
From

About the Antidepressant Market

The Antidepressant market is a subset of the Mental Disorders Drugs market, which includes medications used to treat mental health conditions such as depression, anxiety, bipolar disorder, and schizophrenia. Antidepressants are the most commonly prescribed medications for treating depression, and are typically divided into two categories: selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). These medications work by increasing the levels of serotonin and norepinephrine in the brain, which can help to improve mood and reduce symptoms of depression. Some of the major companies in the Antidepressant market include Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, and Bristol-Myers Squibb. These companies produce a variety of antidepressants, including SSRIs and SNRIs, as well as other medications used to treat mental health conditions. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.